Le médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union européenne pour le prurit cholestatique lié au syndrome d’Alagille, une maladie hépatique rare
September 23, 2024 07:13 ET
|
Ipsen Pharma
Kayfanda® (odévixibat) a été approuvé comme nouvelle option thérapeutique pour le prurit cholestatique chez l’enfant de six...
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
September 23, 2024 07:13 ET
|
Ipsen Pharma
Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver...
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
September 20, 2024 08:57 ET
|
Ipsen Pharma
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows...
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
September 16, 2024 08:45 ET
|
Ipsen Pharma
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in advanced pancreatic and...
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
September 15, 2024 08:45 ET
|
Ipsen Pharma
L’essai portant sur Cabometyx® (cabozantinib) en association avec l’atézolizumab a démontré une tendance positive à l’amélioration de l’un des critères d’évaluation principaux de la survie globale,...
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
September 15, 2024 08:45 ET
|
Ipsen Pharma
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet...
Ipsen - Août 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
September 04, 2024 12:00 ET
|
Ipsen Pharma
Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement...
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
September 04, 2024 12:00 ET
|
Ipsen Pharma
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16...